obesity

News

Digital support reduces GLP-1 dose needed for weight loss

Combining weight-loss drugs with online patient support can achieve results that match the drugs given on their own, but with a much-reduced dose.

News

More data backs Zepbound over Wegovy for weight loss

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo Nordisk.

News

Lilly hit as PBM drops Zepbound, but retains Wegovy

Shares in Eli Lilly have weakened after pharmacy benefit manager CVS Health said it would no longer cover its weight-loss therapy Zepbound.

News

Stethoscope on a tablet with digital globe overlain

Novo Nordisk unleashes Wegovy telehealth blitz

Novo Nordisk has enlisted the aid of major telehealth companies as it tries to dominate the self-pay market for obesity drugs in the US.

News

Lilly soars on first data for oral obesity candidate

Shares in Eli Lilly rose sharply in pre-market trading today after it reported phase 3 results for oral diabetes and weight-loss drug orforglipron.

News

Pfizer's weight-loss aspirations are dealt a heavy blow

Pfizer has been forced to discontinue its oral GLP-1 receptor agonist danuglipron after seeing signs of liver toxicity in late-stage clinical testing.

Digital support reduces GLP-1 dose needed for weight loss

More data backs Zepbound over Wegovy for weight loss

Lilly hit as PBM drops Zepbound, but retains Wegovy

Novo Nordisk unleashes Wegovy telehealth blitz

Lilly soars on first data for oral obesity candidate

Pfizer's weight-loss aspirations are dealt a heavy blow

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

obesity

Editor's Picks